GoKawiilHealth technology startup Signos announced a $20 million funding round on Wednesday, growing its foothold in the GLP-1-fueled weight loss market and expanding its partnership with medical device giant Dexcom .
Google Ventures, Dexcom and Blue Cross Blue Shield of Alabama invested in this latest round, which includes a new distribution deal to put Signos' subscription plans on Dexcom's direct-to-consumer site.
"Dexcom's investment really reflected the shared belief in the future of glucose biosensing beyond diabetes management," Signos CEO Sharam Fouladgar-Mercer told CNBC. "Their biosensor provides glucose data. We translate that into actual guidance."
Signos makes an artificial intelligence-powered glucose monitoring system designed to help with healthy weight loss, the first of its kind to be cleared by the Food and Drug Administration, approved in 2025.
It uses Dexcom's off-the-shelf continuous glucose monitor to measure how a user's real-time lifestyle choices can affect their health, like meal choices, sleep and stress levels. From there, the platform gives personalized recommendations to build healthier habits.
"Nobody wants to have a PhD in statistics to figure out their own body, and so we're really helping translate these glucose insights into actual recommendations, and then the pattern recognition's designed to support healthier habits and sustainable weight management," Fouladgar-Mercer told CNBC.
The startup declined to comment on its valuation following the round.